Information Provided By: 
Fly News Breaks for June 27, 2016
ALXN
Jun 27, 2016 | 06:29 EDT
Citi analyst Robyn Karnauskas upgraded Alexion Pharmaceuticals to Buy saying the post-Brexit vote selloff offers a good entry point into the name. The stock closed Friday down 9%, or $10.58, to $112.99. The analyst's currency analysis suggests no impact from recent moves and she believes the current valuation assumes the worst for the shares. Alexion is currently trading "near our Dark-Sky valuation" of $112 per share, Karnauskas tells investors in a research note. She keeps a $151 price target for the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
